Neurocrine Biosciences (NBIX) Operating Expenses: 2009-2020
Historic Operating Expenses for Neurocrine Biosciences (NBIX) over the last 12 years, with Dec 2020 value amounting to $882.9 million.
- Neurocrine Biosciences' Operating Expenses fell 16.94% to $251.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $858.8 million, marking a year-over-year decrease of 4.80%. This contributed to the annual value of $882.9 million for FY2020, which is 23.34% up from last year.
- Latest data reveals that Neurocrine Biosciences reported Operating Expenses of $882.9 million as of FY2020, which was up 23.34% from $715.8 million recorded in FY2019.
- Neurocrine Biosciences' 5-year Operating Expenses high stood at $882.9 million for FY2020, and its period low was $162.4 million during FY2016.
- For the 3-year period, Neurocrine Biosciences' Operating Expenses averaged around $671.0 million, with its median value being $715.8 million (2019).
- Data for Neurocrine Biosciences' Operating Expenses shows a peak YoY spiked of 80.44% (in 2017) over the last 5 years.
- Over the past 5 years, Neurocrine Biosciences' Operating Expenses (Yearly) stood at $162.4 million in 2016, then skyrocketed by 80.44% to $293.0 million in 2017, then soared by 41.44% to $414.4 million in 2018, then skyrocketed by 72.73% to $715.8 million in 2019, then increased by 23.34% to $882.9 million in 2020.